ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 403,68
1,67%
Dow Jones
42 732,13
0,00%
DAX
20 124,57
1,08%
Brent Oil
76,735
0,30%
Bitcoin
99 214,19
0,90%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Innoviva Inc (INVA) Cours

Innoviva Inc

Innoviva Inc (INVA)

NASDAQ
17,52
0,12
(0,69%)
Fermé 04 Janvier 10:00PM
Retardé de 15 minutes
17,52
0,00
( 0,00% )
Avant marché: 1:26PM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
17,52
Prix Achat
17,46
Prix Vente
19,20
Volume échangé
-
0,00 Fourchette du Jour 0,00
14,325 Plage de 52 semaines 21,28
Cap du marché
1,097B
Clôture Veille
17,52
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
657 567
Actions en circulation
62 601 081
Rendement du Dividende
-
Ratio Cours sur Bénéfices
6,10
Bénéfice par action (BPA)
2,87
Chiffre d'affairess
310,46M
Bénéfice net
179,72M

À propos de Innoviva Inc

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta an... Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Wilmington, Delaware, USA
Fondé
-
Innoviva Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker INVA. Le dernier cours de clôture d'Innoviva était de US$17,52. Au cours de la dernière année, les actions de Innoviva ont été négociées dans une fourchette de prix de US$ 14,325 à US$ 21,28.

Innoviva compte actuellement 62 601 081 actions en circulation. La capitalisation boursière d'Innoviva est de US$1,10 milliard. Innoviva a un ratio cours/bénéfice (ratio PE) de 6.10.

INVA Dernières nouvelles

Plus de nouvelles

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea...

16 Décembre 2024
Business Wire

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as...

26 Novembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

22 Novembre 2024
Edgar (US Regulatory)

Innoviva to Participate in the UBS Global Healthcare Conference

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as...

12 Novembre 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

06 Novembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 Novembre 2024
Edgar (US Regulatory)

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics’ (IST) marketed portfolio achieved U.S...

06 Novembre 2024
Business Wire

Innoviva to Participate in Upcoming Investor Conferences

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as...

04 Septembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

22 Août 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

31 Juillet 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.050.28620492272517.4717.78517.2649390817.41812982CS
4-1.53-8.0314960629919.0519.2817.2665494618.05652383CS
12-2.28-11.515151515219.821.2817.2665756719.06619247CS
261.086.5693430656916.4421.2816.3857503918.88485761CS
520.995.989110707816.5321.2814.32559388117.16768333CS
1560.372.1574344023317.1521.2810.6472133815.30622764CS
2603.7627.325581395313.7621.287.5870913914.5340376CS

INVA - Frequently Asked Questions (FAQ)

What is the current Innoviva share price?
The current share price of Innoviva is US$ 17,52
How many Innoviva shares are in issue?
Innoviva has 62 601 081 shares in issue
What is the market cap of Innoviva?
The market capitalisation of Innoviva is USD 1,1B
What is the 1 year trading range for Innoviva share price?
Innoviva has traded in the range of US$ 14,325 to US$ 21,28 during the past year
What is the PE ratio of Innoviva?
The price to earnings ratio of Innoviva is 6,1
What is the cash to sales ratio of Innoviva?
The cash to sales ratio of Innoviva is 3,53
What is the reporting currency for Innoviva?
Innoviva reports financial results in USD
What is the latest annual turnover for Innoviva?
The latest annual turnover of Innoviva is USD 310,46M
What is the latest annual profit for Innoviva?
The latest annual profit of Innoviva is USD 179,72M
What is the registered address of Innoviva?
The registered address for Innoviva is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
Which industry sector does Innoviva operate in?
Innoviva operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MEGLMagic Empire Global Limited
US$ 1,33
(136,61%)
54,1M
SPRCSciSparc Ltd
US$ 1,11
(110,27%)
27,52M
ARBEArbe Robotics Ltd
US$ 4,66
(77,19%)
18,15M
KITTNauticus Robotics Inc
US$ 5,74
(51,05%)
18M
BAOSBaosheng Media Group Holdings Ltd
US$ 4,896
(50,65%)
5,84M
GCTKGlucoTrack Inc
US$ 0,1929
(-34,23%)
2,4M
ACONAclarion Inc
US$ 0,211
(-29,29%)
9,11M
CLROClearOne Inc
US$ 0,988
(-24,58%)
859,02k
MLYSMineralys Therapeutics Inc
US$ 10,01
(-21,49%)
17
MFImF International Ltd
US$ 1,01
(-21,09%)
761,52k
CNSPCNS Pharmaceuticals Inc
US$ 0,1528
(24,23%)
93,68M
MEGLMagic Empire Global Limited
US$ 1,33
(136,61%)
54,1M
SPRCSciSparc Ltd
US$ 1,10
(108,37%)
27,52M
EKSOEkso Bionics Holdings Inc
US$ 1,06
(45,21%)
24,89M
MBOTMicrobot Medical Inc
US$ 2,54
(18,69%)
22,81M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
INVA
Innoviva
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés